In Parkinson’s disease, it decreases α-synuclein aggregation by targeting the SNCA gene and restores mitochondrial function by correcting mutations in LRRK2 and PINK1 (Mansour and El-Khatib, 2023). This evidence concerns the gene LRRK2 and Parkinson disease.